BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38289994)

  • 1. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
    Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
    Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative Hyperselection of Patients With
    Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
    Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
    J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
    Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
    Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in
    Modest DP; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; Fischer von Weikersthal L; Caca K; Kretzschmar A; Goekkurt E; Haas S; Kurreck A; Stahler A; Held S; Jarosch A; Horst D; Reinacher-Schick A; Kasper S; Heinemann V; Stintzing S; Trarbach T
    J Clin Oncol; 2022 Jan; 40(1):72-82. PubMed ID: 34533973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212).
    Heinrich K; Karthaus M; Fruehauf S; Graeven U; Mueller L; König AO; von Weikersthal LF; Caca K; Kretzschmar A; Goekkurt E; Haas S; Alig AHS; Kurreck A; Stahler A; Held S; Sommerhäuser G; Heinemann V; Stintzing S; Trarbach T; Modest DP
    ESMO Open; 2023 Aug; 8(4):101568. PubMed ID: 37441876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    Sommerhäuser G; Kurreck A; Beck A; Fehrenbach U; Karthaus M; Fruehauf S; Graeven U; Mueller L; Koenig AO; V Weikersthal LF; Goekkurt E; Haas S; Stahler A; Heinemann V; Held S; Alig AHS; Kasper S; Stintzing S; Trarbach T; Modest DP
    Eur J Cancer; 2023 Jan; 178():37-48. PubMed ID: 36399909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
    Ballhausen A; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; von Weikersthal LF; Sommerhäuser G; Alig AHS; Goekkurt E; Meyer-Knees JW; Kurreck A; Stahler A; Held S; Kasper S; Heinrich K; Heinemann V; Stintzing S; Trarbach T; Modest DP
    Eur J Cancer; 2023 Sep; 190():112955. PubMed ID: 37454537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
    Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
    JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
    Raimondi A; Nichetti F; Stahler A; Wasan HS; Aranda E; Randon G; Kurreck A; Meade AM; Díaz-Rubio E; Niger M; Stintzing S; Palermo F; Trarbach T; Prisciandaro M; Sommerhäuser G; Fisher D; Morano F; Pietrantonio F; Modest DP
    Eur J Cancer; 2023 Sep; 190():112945. PubMed ID: 37441940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
    Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
    Sommerhäuser G; Karthaus M; Kurreck A; Ballhausen A; Meyer-Knees JW; Fruehauf S; Graeven U; Mueller L; Koenig AO; Weikersthal LFV; Goekkurt E; Haas S; Stahler A; Heinemann V; Held S; Alig AHS; Kasper-Virchow S; Stintzing S; Trarbach T; Modest DP
    Int J Cancer; 2024 Mar; 154(5):863-872. PubMed ID: 37840339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
    Manca P; Corallo S; Randon G; Lonardi S; Cremolini C; Rimassa L; Bergamo F; Antoniotti C; Smiroldo V; Zaniboni A; Murialdo R; Tampellini M; Tomasello G; Clavarezza M; Racca P; Antista M; Raimondi A; Prisciandaro M; Pagani F; Palermo F; Greco FG; Vaiani M; Di Bartolomeo M; de Braud F; Calareso G; Morano F; Pietrantonio F
    Eur J Cancer; 2021 Feb; 144():31-40. PubMed ID: 33321462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.